{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:14:57Z","timestamp":1792610097821,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ymgme.2021.03.006","type":"journal-article","created":{"date-parts":[[2021,3,14]],"date-time":"2021-03-14T20:30:46Z","timestamp":1615753846000},"page":"100-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy"],"prefix":"10.1016","volume":"133","author":[{"given":"Paula","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2021.03.006_bb0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"5","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2741\/4490","article-title":"Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment","volume":"21","author":"Harmatz","year":"2017","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10545-011-9410-9","article-title":"Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) clinical surveillance program (CSP)","volume":"36","author":"Hendriksz","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","article-title":"Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"134A","author":"Swiedler","year":"2005","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10545-012-9474-1","article-title":"Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series","volume":"35","author":"Th\u00fcmler","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","article-title":"Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance","volume":"14","author":"Akyol","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0050","first-page":"89","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"3","author":"Decker","year":"2010","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0055","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age - a sibling control study","volume":"77","author":"McGill","year":"2010","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4238\/gmr.15017850","article-title":"Impact of early enzyme-replacement therapy for mucopolysaccharidosis VI: results of a long-term follow-up of Brazilian siblings","volume":"15","author":"Franco","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0065","first-page":"69","article-title":"Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-year follow up","volume":"13","author":"Furujo","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1047951113000152","article-title":"Advantages of early replacement therapy for mucopolysaccharidosis type VI: echocardiographic follow-up of siblings","volume":"24","author":"Leal","year":"2014","journal-title":"Cardiol. Young"},{"issue":"122","key":"10.1016\/j.ymgme.2021.03.006_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2017.03.008","article-title":"The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"2017","author":"Harmatz","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0080","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10545-013-9654-7","article-title":"Galsulfase (Naglazyme\u00ae) therapy in infants with mucopolysaccharidosis VI","volume":"37","author":"Harmatz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/J006v27n04_06","article-title":"Review of the bruininks-oseretsky test of motor proficiency, second edition (BOT-2)","volume":"27","author":"Deitz","year":"2007","journal-title":"Phys. Occup. Ther. Pediatr."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0894-1130(03)80019-4","article-title":"Development of the functional dexterity test (FDT): construction, validity, reliability, and normative data","volume":"16","author":"Aaron","year":"2003","journal-title":"J. Hand Ther."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0095","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jhsa.2013.08.123","article-title":"Hand dexterity in children: administration and normative values of the functional dexterity test","volume":"38","author":"Gogola","year":"2013","journal-title":"J. Hand. Surg. [Am.]"},{"key":"10.1016\/j.ymgme.2021.03.006_bb0100","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S1297-319X(02)00432-3","article-title":"Validation of the French version of the childhood health assessment questionnaire (CHAQ) in juvenile idiopathic arthritis","volume":"69","author":"Pouchot","year":"2002","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ymgme.2021.03.006_bb0110","first-page":"1","article-title":"Growth charts for individuals with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"18","author":"Quartel","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2106\/00004623-197961050-00017","article-title":"Normal range of motion of joints in male subjects","volume":"61","author":"Boone","year":"1979","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1212\/WNL.0000000000003466","article-title":"Normative reference values for strength and flexibility of 1,000 children and adults","volume":"88","author":"McKay","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2021.03.006_bb0125","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1164\/rccm.200607-883OC","article-title":"Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years","volume":"176","author":"Li","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0130","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/adc.2007.123653","article-title":"The 6-minute walk test: normal values for children of 4-11 years of age","volume":"93","author":"Lammers","year":"2008","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0135","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.apmr.2015.03.018","article-title":"Normative values for grip and pinch strength for 6- to 19-year-olds","volume":"96","author":"McQuiddy","year":"2015","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/jimd.12079","article-title":"Enzyme replacement therapy outcomes across the disease spectrum: findings from the mucopolysaccharidosis VI clinical surveillance program","volume":"42","author":"Harmatz","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jimd.12028","article-title":"Clinical effectiveness of enzyme replacement therapy with galsulfase in mucopolysaccharidosis type VI treatment: systematic review","volume":"42","author":"Gomes","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0155","first-page":"19","article-title":"Mucopolysaccharidosis type VI on enzyme replacement therapy since infancy: six years follow-up of four children","volume":"5","author":"Horovitz","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0160","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.1993.03510140062030","article-title":"Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction","volume":"270","author":"Bittner","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2021.03.006_bb0165","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0002-9149(01)01975-0","article-title":"Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy","volume":"88","author":"Shah","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0170","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/milmed\/159.10.644","article-title":"Determinants of achievement in stair climbing as an exercise test","volume":"159","author":"Bolton","year":"1994","journal-title":"Mil. Med."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","article-title":"Early initiation of enzyme replacement therapy for the mucopolysaccharidoses","volume":"111","author":"Muenzer","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0180","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/ijms21082975","article-title":"Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations","volume":"21","author":"Parini","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10545-013-9649-4","article-title":"Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy","volume":"37","author":"Kampmann","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0190","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0195","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00417-008-1030-1","article-title":"Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis?","volume":"247","author":"Pitz","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0200","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1755-3768.2010.02085.x","article-title":"Corneal hysteresis in mucopolysaccharidosis I and VI","volume":"90","author":"Fahnehjelm","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0205","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/ajmg.a.38459","article-title":"Genotypic-phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey","volume":"173","author":"Kili\u00e7","year":"2017","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2021.03.006_bb0210","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.03.006_bb0215","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:29:02Z","timestamp":1761089342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1096719221000615"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}